Physical activity program for CLL patients on ibrutinib

This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.

This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.

This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.

This study looks at how changing your diet and exercise routine affects your health if you have CLL. It's testing whether a personalized energy balance plan can help you feel better and manage your disease.

This trial tests whether a tailored, home-based exercise plan can improve exercise capacity (how far and how safely you can be active) in people receiving cancer treatments that may affect the heart. It may help you build safer stamina while monitoring your heart health.

This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.